Similarly, emerging data regarding GLP-1 agonists also suggest a possible role of these drugs in preventing disease progression and enhancing antitumoral response in patients with hepatocellular carcinoma (HCC) by enhancing NK cells antitumoral effect and reversing obesity-induced immune-impairment [121]. Here, GLP1R is linked to hepatocellular carcinoma.